Small aggregates of the protein amyloid-beta (A-beta), called oligomers, have been identified as being the primary cause of brain cell death in Alzheimer’s disease. The investigators identified an amyloid-beta oligomer (ABO)-targeting site, and confirmed that specific antibodies that recognize this site, exclusively detect amyloid-beta oligomers in the brains and spinal fluids of Alzheimer’s disease patients. The team encountered multiple technical limitations during this project, resulting in few defined results thus far. However, new, potentially therapeutic, antibodies have been developed. The team has identified 5 additional ABO specific epitopes and cognate antibodies, owned by UBC and exclusively licensed to ProMIS Neurosciences. Some of these antibodies appear to have greater binding responses to their target than the antibody used for this work. The team hope to validate these novel ABO-antibodies, and commercialize them as therapeutic candidates. Moreover, a paper detailing the discovery and characterization of a specific epitope which is critical to the seeding pathology of amyloid-beta, has been published in ACS Chemical Neuroscience.